The Efficacy of Subconjunctival Bevacizumab in Diabetic Macular Edema
NCT ID: NCT02796183
Last Updated: 2016-06-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2015-01-31
2016-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intravitreal Bevacizumab for Diabetic Macular Edema
NCT00703235
Efficacy, Safety and Tolerability of Repeated Dosis of Intravitreous Bevacizumab in Uveitic Macular Oedema
NCT01095809
Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema
NCT00417716
The Effect of Bevacizumab and Ziv-aflibercept in Diabetic Macular Edema
NCT02645734
Bevacizumab Versus Combined Bevacizumab and Triamcinolone for Refractory Diabetic Macular Edema; a Randomized Clinical Trial
NCT00370422
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diabetic macular edema
Bevacizumab (Altuzan) was injected subconjunctival space of the patients.
Subconjunctival bevacizumab (Altuzan)
Subconjunctival injections of Altuzan 3.75mg were applied in order to eliminate the macular edema.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Subconjunctival bevacizumab (Altuzan)
Subconjunctival injections of Altuzan 3.75mg were applied in order to eliminate the macular edema.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No intravitreal injection in last 3 months.
* No retinal laser photocoagulation in last 6 months
* Not have any other macular disease causing macular edema
Exclusion Criteria
* Intravitreal injection in last 3 months.
* Retinal laser photocoagulation in last 6 months
* Have any other macular disease causing macular edema
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ondokuz Mayıs University
OTHER
Neon Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Volkan YETER
MD
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2015-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.